Pruritus Therapeutics Market is estimated to reach at a CAGR of 6.1% during the forecast period (2023-2030). Pruritus Therapeutics Market study analysis offers an in-depth outlook on the market containing quantitative and qualitative data. It gives an outlook and forecast of the global market based on market segmentation. It also provides global Pruritus Therapeutics Market size, and growth, along with the latest trends, opportunities, and forecast till 2029 for the global market with esteem to major countries such as the United States, Canada, Brazil, Germany, Italy, Spain, United Kingdom, Russia, European countries, United Arab Emirates, Saudi Arabia, South Africa, Japan, China, India, South Korea, Australia, and rest of the countries over the globe.
Among all regions, the North American region is expected to hold the largest share of the global market over the forecast period. Pruritus Therapeutics Market in the United States and Canada produces the utmost share. Whereas the European Pruritus Therapeutics Market is projected to continue its presence globally during the period of 2023- 2030.
Pruritus Therapeutics Market Dynamics and Trends
The global pruritus therapeutics market is growing due to several factors, such as the increasing incidence of dermatological disorders influencing the occurrence of pruritus and the growing demand for proper diagnostics and therapeutics to treat such medical conditions.
The development of new therapeutics for pruritus is forcing global market growth.
The development of new targeted therapies for different pruritus is driving the growth of the global pruritus therapeutics market. For instance, the development of Duplimab, which is a monoclonal antibody that specifically targets interleukin-4 receptors that are involved in the progression of the inflammatory response with these other novel therapeutics, for example, Crisaborole 2% ointment and others are in the pipeline of major key market players for topical medication including the Janus kinase inhibitors. Furthermore, the approval of these newly developed therapeutics by different regulatory bodies propels the market towards growth. For instance, in June 2022, Dupixent (Duplimab), developed by Sanofi, is the first biologics medicine validated by the United States Food and Drug Administration to treat moderate to severe dermatitis in children aged 6 months to 5 years. These market events and the development of new therapeutics are fueling the market growth globally.
The lack of awareness and incidences of drug side effects will become a hurdle in the pruritus therapeutics market growth.
However, the lack of awareness towards therapeutics for pruritus and the associated side effects associated with pruritus therapeutics hinder the market’s growth.
Industry analysis
The pruritus therapeutics market report will provide an in-depth analysis of the market based on various industry factors such as porter`s five forces, research and developments, epidemiology, regulatory analysis, pricing analysis and pipeline analysis, Etc.
COVID-19 Impact Analysis on Pruritus Therapeutics Market
The American Contact Dermatitis Society informed that the covid-19 pandemic had increased the number of contact dermatitis cases. Amidst covid-19, the CDC recommended repetitive hand hygiene with soaps, detergents, and hand sanitization through alcohol-containing hand sanitizers, which lead to the integrity and integrity function alteration in the skin barrier, raising the risk of dermatitis. Also, during the covid-19 outbreak, healthcare professionals were suggested to employ personal protective kits, which have caused a rise in the number of healthcare professionals experiencing contact dermatitis, positively impacting the pruritus therapeutics market.
Pruritus Therapeutics Market Segmentation Analysis
The corticosteroids will dominate the pruritus therapeutics market during the forecast period (2023-2030).
The corticosteroids segment accounted for the highest market share in 2021 and is expected to dominate the Pruritus therapeutics market during the forecast period (2022-2029) since corticosteroids are widely used as the first line of treatment for acute pruritus associated with moderate to severe inflammatory skin diseases, such as AD, allergic contact dermatitis, psoriasis and lichen planus. Corticosteroids are activated glucocorticoid receptors that inhibit cytokine activation, thereby decreasing local inflammation and indirectly controlling pruritus. More than 30 different topical steroid formulations are available in the United States, and these are prepared on different bases (e.g., solution, lotion, cream or ointment). Topical corticosteroids range in potency from low (Class VII) to high or ultra-potent (Class I). It is generally accepted that the clinical efficacy to treat inflammation, and indirectly pruritus, correlates with steroid potency.
Pruritus Therapeutics Market Geographical Share
North America is subjugating the pruritus therapeutics market.
North America dominated the pruritus therapeutics market in 2021. It is estimated that North America will command the global pruritus therapeutics market during the forecast period (2022-2029) since most key market players are headquartered in North America and are involved in developing new drug therapies such as biologics. Examples are Bausch Health, Astellas Pharma U.S.Inc., Pfizer Inc., Mylan, Bayer AG, Allergen, Eli Lilly, and many more. Also, owing to the health care sector developments, organizations and societies are actively looking out for pruritus and government initiatives for spreading awareness about pruritus. For instance, founded in 1989, the American Contact Dermatitis Society is focused on pruritus with over 2,500 healthcare professionals in the field of pruritus and related skin inflammatory diseases. Also, the North American Contact Dermatitis Group is helping thousands of people make informed, evidence-based skin care decisions. These facts show that the North American region will dominate the pruritus therapeutics market over the forecast period.
Pruritus Therapeutics Companies and Competitive Landscape
The pruritus therapeutics market is competitive, with few major players competing to gain market share. Some major players in the global pruritus therapeutics market include Allergan Inc., Amgen Inc., Astellas Pharma Inc., CARA Therapeutics, Novartis AG, Teva Pharmaceutical Industries Ltd, Pfizer, Sanofi, GlaxoSmithKline, Merck, among others. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations contributing to the global Pruritus Therapeutics market’s growth. For instance, in January 2022, Pfizer acquired U.S.FDA approval for its Cibinqo (Adrocitinib), an oral once-a-day Janus kinase inhibitor for treating adults suffering from dermatitis. Also, in April 2022, Leo Pharma presented its interim long-term efficacy data for Adbry (Tralokinumab-ldrm). Such incidences create a competitive environment in the Pruritus Therapeutics market.
Leo Pharma
Overview
Leo Pharma is a leading company in the dermatology market, founded in 1908 and headquartered in Denmark. It is primarily focused on research and development to advance the science of dermatology.
Product Portfolio
Leo Pharma’s dermatological product portfolio has Adtralza, Dovobet, Dovonex, Enstilar, Finacea, Kyntheum, Protopic, Skinoren, Fucidin, and Fucibet.
The global pruritus therapeutics market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) page.